Latest News and Press Releases
Want to stay updated on the latest news?
-
SAN DIEGO, Nov. 19, 2018 (GLOBE NEWSWIRE) -- In support of an ongoing partnership with Daiichi Sankyo, Invivoscribe is pleased to announce submission of the LeukoStrat® CDx FLT3 Mutation Assay to...
-
SAN DIEGO, Nov. 19, 2018 (GLOBE NEWSWIRE) -- Im Rahmen der bestehenden Partnerschaft mit Daiichi Sankyo freut sich Invivoscribe, die Einreichung des Zulassungsantrags für den LeukoStrat® CDx FLT3...
-
SAN DIEGO, 19 nov. 2018 (GLOBE NEWSWIRE) -- En soutien à un partenariat en cours avec Daiichi Sankyo, Invivoscribe a le plaisir d'annoncer la soumission du LeukoStrat® CDx FLT3 Mutation Assay (test...
-
SAN DIEGO, Nov. 19, 2018 (GLOBE NEWSWIRE) -- Em suporte a uma contínua parceria com a Daiichi Sankyo, a Invivoscribe tem o prazer de anunciar o envio do Ensaio de mutação LeukoStrat® CDx FLT3 à PMDA...
-
샌디에이고, Nov. 19, 2018 (GLOBE NEWSWIRE) -- Daiichi Sankyo와의 지속적인 파트너십의 일환으로, Invivoscribe가 LeukoStrat® CDx FLT3 Mutation Assay를 퀴자티닙의 동반 진단 기기로 사용하기 위해 일본 PMDA(Pharmaceuticals and Medical Devices...
-
SAN DIEGO, Nov. 19, 2018 (GLOBE NEWSWIRE) -- Untuk menyokong perkongsian berterusan dengan Daiichi Sankyo, Invivoscribe berbangga mengumumkan penghantaran Asai Mutasi LeukoStrat® CDx FLT3 ke PMDA...
-
美國加州聖地牙哥, Nov. 19, 2018 (GLOBE NEWSWIRE) -- 訊：為支援與Daiichi Sankyo的持續合作關係，Invivoscribe很高興宣佈，已向PMDA（製藥和醫療器械機構）提交LeukoStrat® CDx FLT3突變檢測作為quizartinib的伴隨診斷，以追隨支援 Daiichi...
-
美国圣地亚哥, Nov. 19, 2018 (GLOBE NEWSWIRE) -- 讯：为了支持与Daiichi Sankyo的持续合作关系，Invivoscribe十分高兴地宣布，已向PMDA（制药和医疗器械机构）提交开展LeukoStrat® CDx FLT3突变检测作为quizartinib的伴随诊断。此前，Daiichi...
-
แซนดิเอโก, Nov. 19, 2018 (GLOBE NEWSWIRE) -- เพื่อสนับสนุนความร่วมมือกับ Daiichi Sankyo บริษัท Invivoscribe ยินดีที่จะประกาศการยื่นเสนอ LeukoStrat® CDx FLT3 Mutation Assay...
-
SAN DIEGO, Nov. 19, 2018 (GLOBE NEWSWIRE) -- Untuk mendukung kemitraan berkelanjutan dengan Daiichi Sankyo, Invivoscribe dengan bangga mengumumkan pengajuan LeukoStrat® CDx FLT3 Mutation Assay untuk...